Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

29.2%

7 terminated/withdrawn out of 24 trials

Success Rate

63.2%

-23.3% vs industry average

Late-Stage Pipeline

33%

8 trials in Phase 3/4

Results Transparency

33%

4 of 12 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 2

8(38.1%)

Phase 3

6(28.6%)

N/A

3(14.3%)

Phase 4

2(9.5%)

Phase 1

2(9.5%)

21Total

Phase 2(8)

Phase 3(6)

N/A(3)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials

NCT07155031Phase 2Withdrawn

Biotin-Acridine Red Cell Exchange Kinetics

Role: lead

NCT03037164Phase 3Active Not Recruiting

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

Role: lead

NCT06697223Phase 2Completed

A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.

Role: lead

NCT05711524Phase 4Completed

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

Role: collaborator

NCT07218185Not Yet Recruiting

Comparative Effectiveness of INTERCEPT Fibrinogen Complex (IFC) and Cryoprecipitate-AHF (Cryo-AHF) for Treatment of Trauma Associated Hemorrhage

Role: lead

NCT07015437Phase 2Recruiting

A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1

Role: lead

NCT03459287Phase 3Completed

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients

Role: lead

NCT07152379Phase 2Not Yet Recruiting

Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs

Role: lead

NCT04426591Phase 1Completed

Red Blood Cell Survival in Sickle Cell Disease

Role: collaborator

NCT04681638Phase 4Terminated

Plasma Resuscitation Without Lung Injury

Role: collaborator

NCT04020224Not ApplicableWithdrawn

INTERCEPT Safety Evaluation on Whole Blood

Role: collaborator

NCT04022889Phase 2Completed

In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days

Role: lead

NCT02549222Completed

A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components

Role: lead

NCT02295501Phase 1Terminated

A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease

Role: lead

NCT03486054Not ApplicableWithdrawn

INTERCEPT Safety Evaluation in Anemic Patients

Role: collaborator

NCT03384407Not ApplicableUnknown

Recovery and Lifespan of Red Blood Cells From Pathogen-reduced, Stored Blood Units

Role: collaborator

NCT02305732Completed

A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components

Role: lead

NCT01740531Phase 3Completed

Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

Role: lead

NCT02653443Phase 2Terminated

A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study

Role: lead

NCT02310412Phase 2Completed

A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma

Role: lead